Delivery Order SPE2DR25D9316-SPE2DR26FSCK2
- Not listed
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for JAKAFI 10 mg tablets under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance is Park Ridge, Illinois. The order has a firm fixed-price structure with an ultimate completion date of March 3, 2026. The PPV-G GEN V is a Defense Logistics Agency...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 27, 2026, with a ceiling value of $25,326.56 for supply of JAKAFI 10 mg tablets (60 count), with ultimate completion by March 2, 2026. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceuticals and medical consumables to support military...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $18,516.41 for supply of JAKAFI 5 mg tablets (60 count) under its Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order is firm fixed price with an ultimate completion date of February 10, 2026. PPV-G GEN V...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 4, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 9, 2026, with a ceiling value of $12,663.27 for JAKAFI 10 mg tablets (60-count units), ultimate completion by March 10, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical...
- The Defense Logistics Agency issued a $12,603.07 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on February 25, 2026, for JAKAFI 25 mg tablets (60-count unit). The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 5, 2026, for $12,663.27 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract for pharmaceutical supply to Department of Defense medical facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance is Park Ridge, IL. The delivery order calls for JAKAFI 10 mg...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for $50,653.12 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count). PPV-G GEN V is a Defense Logistics Agency single-award Indefinite Delivery Contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense military...
- <p>The Defense Logistics Agency issued a $72,615.58 delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).</p> <p>DMS Pharmaceutical Group is a woman-owned small business. Place of performance is Park Ridge, Illinois. Ultimate completion date is March 3, 2026. The order is priced firm fixed price with no set-aside designation.</p>
- SPE2DR25D9316Indefinite Delivery Contract
- SPE2DR25D9316-SPE2DR26FSCK2Delivery Order
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 9, 2026, for JAKAFI 5 mg tablets (60-count units) with a ceiling value of $25,441.84 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The order is firm fixed price with place of performance in Park Ridge, IL 60068 and an ultimate completion date of March 10, 2026. The PPV-G GEN V is a Defense Logistics Agency-administered indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award IDC under this program (contract SPE2DR, awarded November 13, 2025) with a $499.999 billion ceiling through December 31, 2036, structured as a 30-month base period with three 30-month option periods.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.4k | 3/8/26 |